 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
4 News |  |
- || Zytux (rituximab biosimilar) / AryoGen
Clinical, Journal: Efficacy and safety of biosimilar rituximab (ZytuxTM) in newly diagnosed patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia. (Pubmed Central) - Dec 17, 2020
Regarding safety profile, Zytux™ demonstrated similar adverse reactions in comparison to MabThera® (Roche Spa). Moreover, the overall response rate in both groups was 85% with complete response achieved in 35% and partial response in remaining 50%.This study concluded that the early results of use of Zytux™ in NHL and CLL were not inferior to reference drug MabThera® in contrast it was comparable and even better in term of safety and efficacy.
- || Zytux (rituximab biosimilar) / AryoGen
Clinical, Observational data, Journal: Evaluating the efficacy and safety of Zytux (Rituximab, AryoGen pharmed) in Iranian multiple sclerosis patients: An observational study. (Pubmed Central) - Jun 9, 2020
Moreover, the overall response rate in both groups was 85% with complete response achieved in 35% and partial response in remaining 50%.This study concluded that the early results of use of Zytux™ in NHL and CLL were not inferior to reference drug MabThera® in contrast it was comparable and even better in term of safety and efficacy. The observed results revealed that the Zytux™ could have a positive and significant effect on all types of MS.